Phase I trial of IL 15 superagonist ALT 803 (IL 15N72D: IL 15R alpha Su/IgG1 Fc complex) in advanced solid tumors: tolerability and correlates of activity

JOURNAL FOR IMMUNOTHERAPY OF CANCER(2017)

引用 0|浏览6
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要